Icecure Medical is trading at $1.42, up 11.67%, with no clear catalyst established for the pre-market rise.
- On October 6, IceCure announced that Legacy Health joined its U.S. ChoICE post-marketing study of ProSense treatment for low-risk breast cancer.
- The FDA-approved study expects to enroll about 400 patients across up to 30 U.S. sites.
- The announcement did not attribute any share-price move to the news; broader-market context was mixed, without a strong same-direction move.